Flynn has worked as CMO at Bentley Systems, a provider of engineering software to the global infrastructure market.
Flynn said that his immediate marketing plans for the company include an upcoming campaign on the company’s ability to provide whole-and multi-genome analysis (WGA).
Ron Ranauro, CEO of GenomeQuest, said: “We’re thrilled to have Tony on the GenomeQuest team. He has a unique ability to understand and communicate value to technical buyers as well as management. He also has an inherent sense of how new software best evolves and develops in organisations and across industries.”
Flynn said: “Specifically, together with pharma, the NIH, hospitals, and many others, we are committed to cracking the ‘information bottleneck’ around whole-genome sequencing. As a result, I think that we’ll soon see a stream of fundamental improvements in health care through the delivery of highly-anticipated ‘personalised medicine.'”
GenomeQuest said that the pharmaceutical firms, biotech companies, core labs, hospitals, clinics, and their researchers can store, analyse, share, and manage their increasing volume of genome sequence, annotation, and variation data with their products.